Article info
PDFHepatology
Paper
HCV substitutions and IL28B polymorphisms on outcome of peg-interferon plus ribavirin combination therapy
- Correspondence to Professor Kazuaki Chayama, Department of Medical and Molecular Science, Division of Frontier Medical Science, Programs for Biomedical Research, Graduate School of Biomedical Science, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima 734-8551, Japan; chayama{at}hiroshima-u.ac.jp
Citation
HCV substitutions and IL28B polymorphisms on outcome of peg-interferon plus ribavirin combination therapy
Publication history
- Revised September 21, 2010
- Accepted September 26, 2010
- First published November 10, 2010.
Online issue publication
October 26, 2017
Article Versions
- Previous version (18 April 2016).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© 2011, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.